相关实验视频

Updated: Jul 9, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

德国脂蛋白阿费雷西斯注册-第十一期年度报告摘要

V J J Schettler¹, N Selke², S Jenke²

¹Center of Nephrology Göttingen GbR, Göttingen, Germany.

Atherosclerosis

|September 29, 2024

概括

在患有高LDL-C和Lp (a) 水平的患者中,脂蛋白非瑞斯 (LA) 显著降低了心血管事件. 这11年的注册数据表明LA是安全和有效的,建立德国脂蛋白阿菲雷西斯注册 (GLAR) 作为世界上最大的.

科学领域:

心脏病学心脏病学
代谢疾病代谢疾病
临床研究临床研究

背景情况:

德国脂蛋白阿菲雷斯注册表 (GLAR) 成立于2012年,收集关于脂蛋白阿菲雷斯 (LA) 的现实数据.
患者接受了最大限度的降脂疗法,包括他类药物,ezetimibe,bempedoic acid和PCSK9抑制剂或抗感觉疗法.

研究的目的:

为了评估长期有效性和安全性,脂蛋白疏松症 (LA) 在患有渐进性动脉样硬化心血管疾病 (ASCVD) 的患者.
分析11年期间接受LA治疗的患者中主要不良心血管事件 (MACE) 和不良事件的发生率.

主要方法:

分析了来自92个德国非中心的1,125名患者 (2012-2022) 的回顾性和前性观察数据.
数据包括超过61,500次LA治疗,重点关注LDL-C和Lp (a) 降低率和LA治疗前和期间的MACE发病率.
患者根据升高的LDL-C和/或Lp (a) 水平进行了分层.

主要成果:

在2022年,脂蛋白疏散 (LA) 实现了LDL-C (68.8%) 和Lp(a) (72.9%) 的显著立即降低.
在LA治疗的前两年观察到MACE的73%降低,随后持续的低率.
患有升高Lp的患者显示,MACE的降低 (85%) 比LDL-C升高的患者 (53%) 高. 副作用的发生率很低 (约. 5%) 主要与穿孔部位问题有关.

结论:

定期的LA治疗在高LDL-C和/或Lp (a) 和渐进的ASCVD患者中显著降低心血管事件率,即使使用最大的降脂疗法.
脂蛋白非热症 (LA) 显示出良好的安全性,在11年内副作用的发生率较低.
GLAR注册表,其广泛的患者数量和观察持续时间,代表了世界上最大的LA注册表,提供了有价值的现实世界的证据.

关键词:

冠心病是一种冠心病.脂质蛋白非热症是指脂质蛋白的非热症.脂蛋白非瑞斯注册登记册中的蛋白质.预防预防预防降低风险降低风险

更多相关视频

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

相关概念视频

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...